KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) EBIT (2016 - 2025)

Historic EBIT for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to $879.9 million.

  • Regeneron Pharmaceuticals' EBIT fell 1113.92% to $879.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $3.6 billion, marking a year-over-year decrease of 1034.4%. This contributed to the annual value of $3.6 billion for FY2025, which is 1034.4% down from last year.
  • As of Q4 2025, Regeneron Pharmaceuticals' EBIT stood at $879.9 million, which was down 1113.92% from $1.0 billion recorded in Q3 2025.
  • In the past 5 years, Regeneron Pharmaceuticals' EBIT ranged from a high of $3.3 billion in Q2 2021 and a low of $591.7 million during Q1 2025
  • In the last 5 years, Regeneron Pharmaceuticals' EBIT had a median value of $1.1 billion in 2022 and averaged $1.3 billion.
  • Per our database at Business Quant, Regeneron Pharmaceuticals' EBIT skyrocketed by 40993.3% in 2021 and then plummeted by 6684.09% in 2022.
  • Over the past 5 years, Regeneron Pharmaceuticals' EBIT (Quarter) stood at $2.6 billion in 2021, then plummeted by 56.56% to $1.1 billion in 2022, then fell by 15.16% to $972.9 million in 2023, then rose by 1.78% to $990.2 million in 2024, then decreased by 11.14% to $879.9 million in 2025.
  • Its EBIT was $879.9 million in Q4 2025, compared to $1.0 billion in Q3 2025 and $1.1 billion in Q2 2025.